Verily Secures $300 Million in Latest Investment Round

Verily has raised $300 million in a funding round to help advance the next phase of its precision health artificial intelligence (AI) strategy. Series X Capital led the investment round, with additional backing from Alphabet, UCHealth, the University of Colorado Anschutz, and others.

Alphabet is now a significant minority investor in Verily, but it no longer has a controlling stake.

“[This] is an important step in our mission to bring the promise of precision health to everyone,” Verily Chairman/CEO Stephen Gillett stated. “From research to care, our customers need solutions that bring the best of clinical and scientific rigor together with AI to deliver the next generation of healthcare—one that is as precise as it is personal. Series X Capital, Alphabet, UCHealth, the University of Colorado Anschutz and our many investors will be fantastic partners in this transformation of healthcare.”

With this latest investment, Verily has transitioned its legal structure from an LLC to a corporation, with the official new name of Verily Health Inc. The organization plans to accelerate its AI-native precision health platform strategy and roadmap to help customers harmonize their healthcare data, model, and deploy actionable intelligence into research and care workflows.

Verily recently announced various commercial partnerships, including a new collaboration with Samsung’s Galaxy Watch to help life sciences customers accelerate clinical research through biomarker development on the Pre platform, and a strategic partnership with Salesforce, announcing integration of the Verily Pre Platform with Agentforce Health to power enterprise precision health solutions. These announcements build on Verily’s recent strategic collaboration with UCHealth, the University of Colorado Anschutz, and RefinedScience, which are using the Verily Pre platform for AI-powered research and care transformation.

“Series X Capital was established in collaboration with Google’s X, The Moonshot Factory, to scale moonshot technologies into consequential, world-changing companies. We are excited to lead this milestone round for Verily, as they drive commercial momentum as a leader in precision health,” Series X Capital Founder/Managing Partner Gideon Yu said.

Verily initially graduated from Google X 10 years ago, as one of Alphabet’s earliest “Other Bets,” with a focus on breakthrough science and health tech innovation.

“At Alphabet, we applaud Verily’s tenacity in using technology to address longstanding challenges in the healthcare industry,” Alphabet and Google President/Chief Investment Officer Ruth Porat commented. “Bringing in new investors, alongside Alphabet’s ongoing involvement, enables Verily to further scale the business to help improve patient outcomes and lower the cost of healthcare delivery through their AI health platform.”

“Partnering with Verily to bring a shared data framework to healthcare data, making it AI‑ready, creates a generational opportunity for UCHealth and for medicine,” UCHealth Chief Medical/Innovation Officer Richard Zane, M.D., said. “This collaboration helps unlock the long‑promised potential of personalized care, benefiting our patients and, ultimately, all patients. It will save lives, and we’re eager to get started.”

Verily is a data platform and technology company purpose-built to power AI-enabled precision health solutions that accelerate research and improve care for individuals and communities. Positioned at the intersection of technology, data science, and healthcare, Verily transforms multimodal health data into insights, models, and actions that make healthcare more personalized, predictive, and precise.